Kymera Therapeutics

Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

– Kymera to receive $150 million upfront  w ith more than $2 billion in potential milestones plus royalty payments  – – Kymera to retain option during clinical development to participate equally in US cost and profit sharing  – CAMBRIDGE, Mass. (July 9, 2020) – Kymera Therapeutics Inc.